Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-70
SponsorNational Medical Research Center for Therapy and Preventive Medicine

About this trial

This prospective randomized open-label study aims to compare the effectiveness of two dual antihypertensive therapy regimens in patients with arterial hypertension and coronary artery disease after elective percutaneous coronary intervention (PCI) with coronary artery stenting.

Patients requiring dual antihypertensive therapy will be randomized to receive either an angiotensin receptor blocker (ARB) combined with a thiazide diuretic or an ARB combined with a dihydropyridine calcium channel blocker.

The study will evaluate blood pressure control, angina symptoms, quality of life, need for treatment intensification, and healthcare utilization during follow-up. Clinical status will be assessed at discharge and during telemedicine follow-up visits at 2 weeks, 4 weeks, and 12 weeks after hospital discharge.

The primary endpoint is the percentage reduction in systolic and diastolic blood pressure. Secondary endpoints include frequency of angina episodes, exercise limitations, patient satisfaction with treatment, and medical consultations during follow-up.

The study is investigator-initiated and plans to enroll at least 207 participants.

Eligibility criteria

Qualifiers

Age 50 to 70 years

Arterial hypertension

Coronary artery disease

Hospitalization for elective percutaneous coronary intervention

Disqualifiers

Refusal or inability to provide informed consent

Acute coronary syndrome

Active malignancy

Pulmonary embolism

Trial design

Treatments tested in this trial

  • Losartan + Hydrochlorothiazide
  • Amlodipine + Azilsartan

Treatment groups

207 Participants
are divided into 2 treatment groups